from Nay 24 Nikkei

時価総額630億円減　世界の株式市場　１カ月で１４％　欧州不安が引き金

With the fears about sovereign dedt crisis in European countries spread, the total values of stock prices in the world stock markets have recently been significantly decreased. In only a month after the mid-April, when they were in the peak after Lehman Shock,the values decreased about 14 percent, with about 630 trillion yen blowing off.

from May 25 Nikkei

米、北朝鮮政策見直し　哨戒艦沈没　韓国、制裁を発動

U.S. President Barack Obama on the 24th instructed his administartive staff to launch on revising U.S. deplomatic policy toward North Korea. With a recent sinking of a South Korean naval vessel in mind,Obama also demanded strengthening cooperation with the South Korean forces in preparing for possible future attacks from North Korea. Meanwhile, South Korea has already started excercising sanctions against North Korea.Given these circumstnaces, tension is now increasing in the Korean Peninsula.

from yesterday's Nikkei

自動車　海外から世界輸出　為替リスクを軽減　トヨタ、米で日本用エンジン　日産、タイから１５カ国向けに

It has recently been learned that many of Japanese automobile makers are going to expand their exports from their overseas factories. Specifically, Toyota Corporation will bring made-in-the U.S. engines back to Japan and also will expand the auto exports to the Middle East countieas and others from its factories in the South East Asian countries.In Nissan Motor Company, they will increase production of the vehicles and parts in the areas of Asia and Europe in order to curb imports from Japan.

Their strategies are in essence that making the best use of their overseas fctories as the bases for their global exports, they wil reduce costs with a mass-production effect and ease the risk of exchange rate fluctuations.

from today's Nikkei

後発薬　仏大手が日本参入　サノフィ、日医工に出資　市場拡大に弾み

According to sources, a French major pharmaceutical company Sanofi-Aventis is likely to enter into a genetic medicine market in Japan. It is reported that the company will have a tie-up with Nichi-Iko Pharmaceutical Company, a Japanese first-ranked genetic medicine maker, in terms of capital and sales relationship, to jointly develop and sell genetic medicines.

Specifically, Sanofi will invest its money equivalent to about 5 billion yen to take a nearly five-percent stake of Nichhi-Iko's cpital.

With a giant comapny, the world's fifth largest in pharmacy, participating in, a domestic generic medicine market will surely get momentum in its expanion.